Welcome to our dedicated page for Cognition Therapeutics news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company based in Pittsburgh, Pennsylvania. Established in 2007, the company is dedicated to discovering and developing small-molecule therapeutics aimed at treating age-related degenerative diseases and disorders of the central nervous system and retina.
At the heart of Cognition Therapeutics' innovation is its proprietary biology and chemistry platforms, which are utilized to identify novel drug targets and create disease-modifying therapies. The company's flagship product candidate, CT1812, is an orally administered small-molecule antagonist designed to breach the blood-brain barrier. CT1812 binds selectively to the S2R complex, potentially offering a unique therapeutic approach for patients.
Current Projects and Achievements:
- CT1812 is currently being evaluated in Phase 2 clinical trials for conditions such as Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD).
- Recent 2023 milestones include completing enrollment for the SHINE Study in mild-to-moderate Alzheimer's disease and initiating new clinical studies for early Alzheimer's and dry AMD.
- The SHIMMER study for mild-to-moderate DLB has also reached its target enrollment, with top-line results anticipated in the latter half of 2024.
The company has made significant strides in advancing its clinical programs. In 2023, the FDA approved the first disease-modifying biologics for Alzheimer’s disease, which has rejuvenated research and investment in this critical area. Cognition Therapeutics is leveraging this momentum in its ongoing research and clinical trials.
Financial Overview:
For the year ending December 31, 2023, Cognition Therapeutics reported cash and cash equivalents of approximately $29.9 million. Additional capital from a March 2024 offering has bolstered their financial position, providing the company with sufficient funds to support operations and capital expenditures through May 2025.
Research and development expenses for 2023 were $37.2 million, an increase from $30.3 million in 2022, reflecting higher costs associated with Phase 2 trials and personnel. General and administrative expenses remained relatively stable at $13.5 million.
The company continues to foster collaborations and partnerships to advance its scientific goals. Notably, the SHIMMER study is supported by a significant grant from the National Institute on Aging (NIA), totaling approximately $30 million.
For ongoing updates and detailed information about Cognition Therapeutics, visit their website at cogrx.com.
Cognition Therapeutics will present in vitro results on the role of sigma-2 receptors and the effect of their drug candidate CT1812 on dry age-related macular degeneration (AMD) at the upcoming ARVO meeting in New Orleans from April 23-27.
CT1812, an orally delivered small molecule, targets sigma-2 receptors and shows potential in modulating biological pathways affected by dry AMD, including immune response and cell survival. The detailed findings will be showcased in poster #C0072 during the conference.
The company is also preparing for a Phase 2 clinical trial of CT1812 for geographic atrophy linked to dry AMD, with clinical site selection currently underway. The drug is under investigation for mild-to-moderate Alzheimer's disease and dementia with Lewy bodies as well.
Cognition Therapeutics announced the publication of a review article in the International Journal of Molecular Sciences discussing the mechanistic rationale for sigma-2 receptor modulation in age-related degenerative diseases including Alzheimer's disease and dementia with Lewy bodies. The article highlights the role of the sigma-2 receptor in neuronal function and its potential as a therapeutic target. Cognition's lead compound, CT1812, aims to advance to Phase 2 clinical trials. The study focuses on restoring synaptic health by targeting cellular processes impaired by neurodegenerative diseases. Cognition’s strategy underscores the unique mechanism of CT1812 in addressing significant unmet medical needs in neurodegeneration.
On March 28, 2023, Cognition Therapeutics (NASDAQ: CGTX) disclosed findings from a meta-analysis involving 24 participants in the Phase 2 SHINE-A study and data from the Phase 1b SPARC study. The results indicate that treatment with CT1812 yields statistically significant effects on key Alzheimer's disease markers, notably improving synapse health and reducing neuroinflammation. Notable changes in cerebrospinal fluid levels of clusterin and prion protein were observed, underscoring CT1812's potential in altering disease processes. These results were presented at the AD/PD™ 2023 conference, enhancing understanding of CT1812's therapeutic effects.
Cognition Therapeutics (Nasdaq: CGTX) has released its fourth video podcast discussing dementia with Lewy bodies (DLB), featuring insights from four neuroscience experts. The podcast highlights the overlap between DLB, Alzheimer’s, and Parkinson’s diseases, including symptoms, clinical features, and the importance of accurate diagnosis. Currently, there are no approved disease-modifying treatments for DLB, which affects about 1.4 million Americans. The company is conducting the Phase 2 SHIMMER study for its lead candidate, CT1812, with a $30M grant from the NIH’s National Institute on Aging to evaluate treatment effects on DLB.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has announced significant progress in its clinical development, including the completion of enrollment in the Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease. The company received FDA clearance for the Phase 2 START study and the IND for a Phase 2 study targeting geographic atrophy due to dry AMD. Financially, the company secured an equity commitment of up to $35 million and raised $6 million through a public offering, with cash reserves expected to fund operations into the second half of 2024. However, Cognition reported a net loss of $21.4 million for 2022, reflecting increased R&D and G&A expenses.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) will present results from a proteomic biomarker meta-analysis of cerebrospinal fluid samples from participants in their Phase 2 SHINE and Phase 1b SPARC studies, focusing on mild-to-moderate Alzheimer's disease. The analysis identified biomarkers of CT1812 activity, which inform the understanding of Alzheimer's progression. A poster presentation is scheduled at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. Additionally, CEO Lisa Ricciardi will participate in a panel on innovative approaches to Alzheimer's research on March 29, emphasizing the importance of rigorous clinical trials.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced a conference call set for March 23, 2023, at 8:00 a.m. ET to review its financial results for the fourth quarter and full year ended December 31, 2022. The results will be released before the market opens on the same day. Participants can access the call via a toll-free dial-in or through a live audio webcast on the company's Investor Relations page. Cognition is focused on developing treatments for neurodegenerative disorders, with its lead candidate CT1812 targeting Alzheimer's and related conditions.
FAQ
What is the current stock price of Cognition Therapeutics (CGTX)?
What is the market cap of Cognition Therapeutics (CGTX)?
What does Cognition Therapeutics, Inc. specialize in?
What is CT1812?
What recent achievements has Cognition Therapeutics made?
How is Cognition Therapeutics funded?
What are the company's main areas of research?
Where is Cognition Therapeutics located?
What are the financial highlights for Cognition Therapeutics in 2023?
How does CT1812 work?
What are some key milestones expected in 2024?
How can I stay updated on Cognition Therapeutics’ progress?
